Observation on the effect of long-acting interferon injection and nucleoside drugs on serum interleukin 37 levels and clinical effect in patients with hepatitis B
Objective To investigate the effect of long-acting interferon injection and nucleoside drugs on serum interleukin 37 levels and clinical effect in patients with hepatitis B.Methods 172 patients with Chronic hepatitis B from the Department of liver disease in our hospital were selected and divided into 2 groups, 86 cases in the control group treated with Entecavir, 86 cases in the experiment group received Polyethylene glycol interferon α-2a treatment on the basis of the control group, serum levels of inflammatory factors, peripheral blood T lymphocyte level, serum level of hepatic fibrosis index, and the clinical effect were compared after the treatment.Results The effective rate in the control group(63.95%)was lower than the experiment group(81.40%), with significant difference (P<0.05), the DNA HBV negative conversion rate, HBeAg negative conversion rate, HBeAg conversion rate and ALT recovery rate in control group after treatment were lower than the experiment group, with significant difference (P<0.05), compared with the control group, serum levels of IL-37、IL-6、IL-18、IL-12 were lower after treatment in the experiment group, peripheral blood levels of CD4 + T lymphocyte and CD4 +/CD8 +ratio were higher, and peripheral blood levels of CD8 +T lymphocyte weaas lower after treatment, serum levels of HA、PCⅢ、Ⅳ-C and LN were lower after treatment, with significant difference (P<0.05).Conclusion Long-acting interferon injection and nucleoside drugs can significantly reduce the serum levels of IL-37, IL-6, IL-18, IL-12 in patients with hepatitis B, reduce the inflammatory reaction, improve the cellular immune function, inhibit liver fibrosis, the clinical effect was good.
NETL
NSTL
万方数据
维普
